BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Vector Partners with Caresyntax to Build Real-World Evidence Programme for Opioid-Sparing Surgical Platform

Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative reg...

July 21, 2026 | News

China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer

SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...

July 21, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC

Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...

July 21, 2026 | News

Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide

Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...

July 21, 2026 | News

Canada and Taiwan Build New Bridges Across AI, Advanced Therapeutics and Precision Health

As biotechnology increasingly converges with artificial intelligence, advanced therapeutics and data-driven healthcare, the next generation of inno...

July 20, 2026 | News

Why Korea, Why Now? Korean Biotech Looks to Taiwan as Asia’s Next Partnership Frontier

Korea’s biotechnology industry is entering a new phase of global ambition. Having established significant capabilities across biopharmaceutical manuf...

July 20, 2026 | News

Creative Life Science Showcases Regenerative Medicine Manufacturing Capabilities at BIO Asia–Taiwan 2026

BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstrea...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...

July 20, 2026 | News

From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing

ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...

July 17, 2026 | Expert Insight

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...

July 17, 2026 | News

Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit

New ready-to-use protein expression kit now available eviCHO Expression Kit simplifies transient protein expression workflows and enables faster, ...

July 17, 2026 | News

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Stay Connected